Deutsche Bank AG Takes Position in Prestige Consumer Healthcare Inc. $PBH

Key Points

• Deutsche Bank acquired 50,795 shares of Prestige Consumer Healthcare in the second quarter, worth approximately $2.4 million and representing a 0.11% stake. Institutional investors and hedge funds collectively own 99.95% of PBH.
• Analyst sentiment remains mixed, with a consensus “Hold” rating and an average price target of $70.75. Canaccord Genuity lowered its target to $72, while Oppenheimer and Weiss Ratings downgraded the stock.
• Prestige exceeded quarterly expectations, reporting $0.98 in EPS versus a $0.89 consensus and revenue of $265.71 million versus $253.02 million expected. Shares opened at $51.27, while management’s fiscal 2027 EPS guidance is $4.55–$4.65.

Deutsche Bank AG acquired a new stake in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 50,795 shares of the company's stock, valued at approximately $2,401,000. Deutsche Bank AG owned 0.11% of Prestige Consumer Healthcare at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Lido Advisors LLC raised its position in shares of Prestige Consumer Healthcare by 5.4% during the 4th quarter. Lido Advisors LLC now owns 3,778 shares of the company's stock valued at $235,000 after buying an additional 192 shares during the period. Cerity Partners LLC raised its position in Prestige Consumer Healthcare by 5.9% in the second quarter. Cerity Partners LLC now owns 3,884 shares of the company's stock valued at $310,000 after purchasing an additional 218 shares during the period. UMB Bank n.a. raised its position in Prestige Consumer Healthcare by 110.1% in the fourth quarter. UMB Bank n.a. now owns 418 shares of the company's stock valued at $26,000 after purchasing an additional 219 shares during the period. Versant Capital Management Inc lifted its stake in shares of Prestige Consumer Healthcare by 47.9% in the 2nd quarter. Versant Capital Management Inc now owns 726 shares of the company's stock valued at $34,000 after purchasing an additional 235 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd lifted its stake in shares of Prestige Consumer Healthcare by 69.8% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 574 shares of the company's stock valued at $35,000 after purchasing an additional 236 shares during the last quarter. 99.95% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

PBH has been the subject of a number of recent analyst reports. Oppenheimer downgraded Prestige Consumer Healthcare from an "outperform" rating to a "market perform" rating in a research report on Thursday, May 14th. Zacks Research raised shares of Prestige Consumer Healthcare from a "strong sell" rating to a "hold" rating in a research note on Monday, August 10th. Canaccord Genuity Group dropped their price target on shares of Prestige Consumer Healthcare from $86.00 to $72.00 and set a "buy" rating for the company in a research report on Friday, May 15th. Finally, Weiss Ratings downgraded shares of Prestige Consumer Healthcare from a "hold (c-)" rating to a "sell (d+)" rating in a research note on Thursday, June 25th. Two research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $70.75.

Prestige Consumer Healthcare News Summary

Here are the key news stories impacting Prestige Consumer Healthcare this week:

• Positive Sentiment: Zacks projects earnings growth from $4.55 per share in FY2027 to $5.06 in FY2028 and $5.25 in FY2029, implying continued profit expansion for Prestige Consumer Healthcare.
• Neutral Sentiment: The firm estimates quarterly EPS of $1.06 for Q2 FY2027, $1.22 for Q3, and $1.30 for Q4. Its FY2027 forecast of $4.55 is broadly aligned with the current $4.56 consensus estimate.
• Neutral Sentiment: Zacks maintained a “Hold” rating on PBH, signaling limited conviction that the projected earnings growth currently warrants a more bullish stance. Prestige Consumer Healthcare analyst estimates
• Negative Sentiment: The update consists primarily of routine estimates for periods extending through FY2029, rather than a fresh earnings beat, guidance increase, or strategic announcement. That lack of a new positive catalyst may be weighing on the stock in the near term.

Prestige Consumer Healthcare Stock Down 1.7%

Shares of PBH opened at $51.27 on Friday. The company's 50-day simple moving average is $50.11 and its 200-day simple moving average is $54.64. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.99 and a current ratio of 3.23. Prestige Consumer Healthcare Inc. has a 1 year low of $42.62 and a 1 year high of $71.07. The stock has a market capitalization of $2.43 billion, a PE ratio of 14.36, a P/E/G ratio of 1.63 and a beta of 0.34.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported $0.98 earnings per share for the quarter, topping the consensus estimate of $0.89 by $0.09. The firm had revenue of $265.71 million for the quarter, compared to the consensus estimate of $253.02 million. Prestige Consumer Healthcare had a net margin of 15.57% and a return on equity of 11.39%. The firm's revenue for the quarter was up 6.5% on a year-over-year basis. During the same period in the prior year, the firm earned $0.90 EPS. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. Analysts forecast that Prestige Consumer Healthcare Inc. will post 4.56 earnings per share for the current fiscal year.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women's health.

Key brands in Prestige's portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women's health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source